Financial Review: SeaStar Medical (NASDAQ:ICU) vs. Pheton (NASDAQ:PTHL)

Pheton (NASDAQ:PTHL) and SeaStar Medical (NASDAQ:ICU) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk.

Valuation & Earnings

This table compares Pheton and SeaStar Medical”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pheton	$450,000.00	8.35	-$660,000.00	N/A	N/A
SeaStar Medical	$766,000.00	14.02	-$24.83 million	($1.65)	-0.19

Pheton has higher earnings, but lower revenue than SeaStar Medical.

Profitability

This table compares Pheton and SeaStar Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pheton	N/A	N/A	N/A
SeaStar Medical	-1,551.08%	-414.50%	-151.13%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Pheton and SeaStar Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pheton	1	0	0	0	1.00
SeaStar Medical	1	0	0	0	1.00

Risk & Volatility

Pheton has a beta of 5.08, suggesting that its share price is 408% more volatile than the S&P 500. Comparatively, SeaStar Medical has a beta of -1.06, suggesting that its share price is 206% less volatile than the S&P 500.

Institutional & Insider Ownership

1.7% of SeaStar Medical shares are held by institutional investors. 1.3% of SeaStar Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Pheton beats SeaStar Medical on 5 of the 9 factors compared between the two stocks.

About Pheton

Pheton Holdings Ltd. operates as a holding company with interests in providing healthcare solutions. The firm through its subsidiaries engages in the development and commercialization of brachytherapy TPS specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company was founded in 1998 and is headquartered in Beijing, China.

About SeaStar Medical

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquartered in Denver, Colorado.